Category: Abiomed Inc.
Here's a look at some of the top regulatory stories for medical device companies this week: Stryker launches Mako robotic hip replacement; Abiomed soars to new all-time high on FDA nod; FDA grants humanitarian use device status to fetal micro-pacemaker; Wright Medical wins FDA nod for Salvation external fixation device; FDA clears Stryker's Lite lumbar plating system
Here's a look at some of the top Wall Street stories for medical device companies this week: Boston Scientific's gain is St. Jude Medical's loss; Abiomed soars to new all-time high on FDA nod; Philips mulls 2016 IPO for lighting biz as bidding war heats up; SteadyMed prices $40m IPO well under range; Becton Dickinson to shed assets after CareFusion buy
, Bain Capital
, Becton Dickinson & Co.
, Boston Scientific
, CareFusion Corp.
, CVC Capital Partners
, Food & Drug Administration (FDA)
, GSR Ventures
, Kohlberg Kravis Roberts & Co. L.P.
, Lattice Power
, Royal Philips
, St. Jude Medical
, SteadyMed Therapeutics
, Abiomed Inc.
, Allergan Inc.
The FDA's approval of Abiomed's flagship Impella 2.5 heart pump sends the company's stock up 18% to an all-time high.
Here's a look at some of the top legal news stories for medical device companies this week: Medtronic's new Ev3 unit pays $1.3m in whistleblower suit; Medtronic settles another whistleblower suit for $2.8m; Ex-NFL great Gault must face SEC fraud charges; Appeals court upholds Abiomed win in shareholders lawsuit; Pelvic mesh lawsuits: Boston Scientific wants 700 Philly cases sent to federal court
A federal appeals court upholds Abiomed's win in a shareholders lawsuit accusing the company of inflating its stock price with rosy predictions for its flagship Impella 2.5 heart pump.
Abiomed (NSDQ:ABMD) logged another win in a shareholders lawsuit accusing it and its management of misleading investors over the prospects for its flagship Impella 2.5 heart pump.
Here's a look at some of the top Wall Street stories for medical device companies this week: Asante Solutions sets IPO terms; Stryker CEO Lobo: M&A is our top priority for cash; Abiomed surges on Q3 numbers, FDA nod; Credit agencies lower Medtronic's rating post-Covidien merger
Abiomed shares surge to an all-time high after the heart pump maker crushes expectations with its fiscal 3rd-quarter results and raises its outlook for the rest of fiscal 2015.
Abiomed (NSDQ:ABMD) shares surged to an all-time high today after the heart pump maker crushed expectations for its fiscal 3rd quarter and raised its outlook on the rest of the year.